Samsrita Labs Ltd
₹ 19.2
0.00%
22 Nov
- close price
About
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
Key Points
- Market Cap ₹ 28.5 Cr.
- Current Price ₹ 19.2
- High / Low ₹ 32.4 / 13.0
- Stock P/E
- Book Value ₹ 8.25
- Dividend Yield 0.00 %
- ROCE -1.71 %
- ROE -2.01 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.42% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.40%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.00 | 3.97 | 3.69 | 1.28 | 0.62 | 1.90 | 1.43 | 0.01 | 0.02 | 0.02 | -0.00 | 0.00 | |
| 0.01 | 0.01 | 4.03 | 3.73 | 1.61 | 1.64 | 4.13 | 3.46 | 0.92 | 0.43 | 1.01 | 0.25 | 0.25 | |
| Operating Profit | -0.01 | -0.01 | -0.06 | -0.04 | -0.33 | -1.02 | -2.23 | -2.03 | -0.91 | -0.41 | -0.99 | -0.25 | -0.25 |
| OPM % | -1.51% | -1.08% | -25.78% | -164.52% | -117.37% | -141.96% | -9,100.00% | -2,050.00% | -4,950.00% | ||||
| -0.00 | 0.08 | 0.09 | 0.05 | 0.01 | -0.00 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | -0.00 | 0.00 | |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 | 0.01 | 0.01 | 0.01 | -0.00 | -0.00 | 0.00 |
| Profit before tax | -0.01 | 0.07 | 0.03 | 0.01 | -0.32 | -1.02 | -2.14 | -1.89 | -0.77 | 1.49 | -0.70 | -0.25 | -0.25 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | |
| -0.01 | 0.07 | 0.03 | 0.01 | -0.32 | -1.02 | -2.14 | -1.89 | -0.77 | 1.50 | -0.71 | -0.25 | -0.25 | |
| EPS in Rs | -0.02 | 0.13 | 0.06 | 0.02 | -0.31 | -0.87 | -1.55 | -1.28 | -0.52 | 1.01 | -0.48 | -0.17 | -0.17 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 19% |
| TTM: | 69% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -21% |
| 3 Years: | -10% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -3% |
| 3 Years: | 1% |
| Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.54 | 5.39 | 5.39 | 5.39 | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | -1.69 | -1.62 | -1.60 | -1.58 | -1.90 | -1.42 | -1.51 | -2.38 | -3.01 | -1.51 | -2.22 | -2.47 | -2.60 |
| -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 1.32 | 1.79 | 2.34 | 2.74 | 2.08 | 2.20 | 2.33 | |
| 0.45 | 0.48 | 2.54 | 1.74 | 0.13 | 1.89 | 1.61 | 2.71 | 3.09 | 1.16 | 0.96 | 1.10 | 1.11 | |
| Total Liabilities | 3.30 | 4.25 | 6.33 | 5.55 | 8.49 | 12.23 | 15.23 | 16.93 | 17.23 | 17.20 | 15.63 | 15.64 | 15.65 |
| -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 3.27 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.92 | 2.15 | 3.03 | 3.26 | 3.26 | 3.26 | 3.26 | -0.00 |
| Investments | -0.00 | 0.85 | -0.00 | -0.00 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 |
| 3.30 | 3.40 | 6.33 | 5.55 | 3.62 | 6.42 | 8.17 | 9.00 | 9.08 | 9.06 | 7.49 | 7.50 | 7.51 | |
| Total Assets | 3.30 | 4.25 | 6.33 | 5.55 | 8.49 | 12.23 | 15.23 | 16.93 | 17.23 | 17.20 | 15.63 | 15.64 | 15.65 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.76 | -0.02 | -0.06 | -3.28 | -3.46 | -1.07 | -0.34 | -0.40 | 0.66 | -0.13 | ||
| -0.85 | 0.85 | -0.00 | -4.87 | -0.94 | -1.26 | -0.89 | -0.23 | -0.00 | -0.00 | -0.00 | ||
| 0.85 | -0.00 | -0.00 | 4.87 | 4.53 | 4.40 | 1.97 | 0.55 | 0.40 | -0.67 | 0.13 | ||
| Net Cash Flow | -0.00 | 0.09 | -0.02 | -0.06 | 0.31 | -0.32 | 0.01 | -0.02 | 0.01 | -0.00 | -0.00 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 528.65 | 498.54 | 932.46 | 1,689.60 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |||
| Inventory Days | -0.00 | -0.00 | -0.00 | 608.33 | -0.00 | -0.00 | ||||||
| Days Payable | 365.00 | |||||||||||
| Cash Conversion Cycle | 528.65 | 498.54 | 932.46 | 1,932.93 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |||
| Working Capital Days | 296.96 | 328.40 | 903.95 | 2,254.76 | 991.26 | 1,115.42 | 146,000.00 | 108,770.00 | 84,132.50 | |||
| ROCE % | -0.35% | 2.11% | 0.79% | 0.26% | -5.26% | -10.91% | -17.78% | -13.51% | -5.43% | 9.87% | -4.56% | -1.71% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Publication of un-audited financials of the company for the quarter ended on 30-09-2024 in the news papers
-
Un-Audited Financial Results For The Quarter Ended On 30-09-2024
11 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11-11-2024
11 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Unaudited Results For The Quarter And Half Year Ended 30.09.2024
2 Nov - Board meeting scheduled for financial results on 11.11.2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
24 Oct - Certificate under Regulation 74(5) for no securities.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products & Services:[1][2]
a) Stem Cell R&D:
Stem Cell Research & Therapy,
Regenerative Medicine, Bio-artificial
organ scaffolds development, nano-biotechnology, Nano-formulation of
cancer Drugs, Molecular genetics,
and Molecular virology, Stem cell
and Cord blood banking
b) New Drug Discovery:
Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease
c) RNA Interference:
For developing a new panel of miRNAs
as a novel Bio Marker
d) Medical Devices:
Extra-corporeal liver support devices, Bioengineering implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, extra-corporeal devices, etc.
e) Molecular Diagnostics:
DNA, RNA, and chromosomal based tests
and Pre-natal and pre-implantation genetic diagnostics, etc.
f) Contract Research Organization:
Synthetic Chemistry, Medicinal Chemistry, Drug Development, API’s process research, scale-up activity, Natural products research, and Analytical services